Evidence map›Paper›PMID 39356620›Full record

ArticleJournal of addiction medicine

The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review.

Oluwole Jegede, Joao P De Aquino, Connie Hsaio, Ebony Caldwell, Melissa C Funaro, Ismene Petrakis, Srinivas B Muvvala

Abstract readScoping Review
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oluwole JegedeFrom the Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven CT (OJ, JPDA, CH, EC, IP, SBM); and Cushing/John Hay Whitney Medical Library, Yale University School of Medicine (MCF).ORCID 0000-0001-6772-7149
Joao P De Aquino
Connie Hsaio
Ebony Caldwell
Melissa C Funaro
Ismene Petrakis
Srinivas B Muvvala

Funding

Combination of THC and CBD as a Novel Treatment for Co-Occurring Opioid Addiction and Chronic PainR01DA060066 · NIDA · YALE UNIVERSITY · PI Joao Paulo De Aquino · 2024 to 2026
$1.3M
Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic PainK23DA052682 · NIDA · YALE UNIVERSITY · PI DE AQUINO, JOAO PAULO · 2021 to 2025
$959k
Pharmacokinetics and Pharmacodynamics of Oral and Vaporized THC in Older AdultsR21DA057240 · NIDA · YALE UNIVERSITY · PI DE AQUINO, JOAO PAULO · 2022 to 2023
$360k
NIDA NIH HHS K23 DA052682NIDA NIH HHS R01 DA060066NIDA NIH HHS R21 DA057240
6 · The paper itself

Abstract

backgroundThe clinical implications of high potency synthetic opioids (HPSO) on medications for opioid use disorder (MOUDs) are not well understood. Although pharmacological interactions are plausible, the clinical significance of such interaction has not been systematically elucidated. This scoping review investigates the relationship between HPSO exposure and various MOUD treatment outcomes.

methodsWe followed PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews) for scoping reviews with extensive a priori search strategy of databases: MEDLINE, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane.

resultsFrom 9149 studies, 34 fulfilled the inclusion criteria. Synthesized data reveal several critical insights: First, there is a variable but high occurrence (38%-80%) of HPSO usage among individuals with MOUDs. Second, MOUDs are linked to a decreased risk of overdoses and deaths associated with HPSO. Third, HPSO consumption is correlated with the risk of precipitated withdrawal when starting buprenorphine. Fourth, low-dose buprenorphine is being recognized as one method to avoid moderate withdrawal symptoms prior to treatment. Lastly, significant gaps exist in human experimental data concerning the effects of HPSO on key factors critical for treating OUD-craving, withdrawal symptoms, and pain.

conclusionsCurrent evidence supports MOUD safety and effectiveness in reducing nonmedical opioid use. Further research is needed to explore HPSO's influence on the acute factors preceding nonmedical opioid use, such as cravings, withdrawal symptoms, and pain. This research could inform the optimization of MOUD dosing strategies. Achieving consensus and harmonizing data across clinical and research protocols could diminish variability, enhancing our understanding of HPSOs effect on MOUD treatment outcomes.

Indexed as

Analgesics, OpioidOpiate Substitution TreatmentOpioid-Related DisordersBuprenorphineDrug InteractionsHumansAnalgesics, OpioidBuprenorphine

Identifiers

PMID39356620
PMCPMC11449257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.